Katelyn Scagnelli
Primary Care · Chelmsford, MANPI 1760634943
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,402 of the $1,976 with a category attached, or 71.0%. It is spread thinly across 18 manufacturers, the largest accounting for just 16.7%. 2025 is the largest year on record at $974, more than ten times the $97 reported in 2021. Among primary care clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $58.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$330
- AstraZeneca$280
- Gilead$230
- Astellas Pharma US Inc$194
- Seagen Inc.$170
- Jazz Pharmaceuticals Inc.$137
- plus $635 from 12 others
What the payments were for
- Consulting fees$28014%
- Food & beverage$1,40271%
- Education$29415%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 9 | $330 |
| AstraZeneca | 1 | $280 |
| Gilead(2 entities) | 2 | $230 |
| Astellas Pharma US Inc | 2 | $194 |
| Seagen Inc. | 4 | $170 |
| Jazz Pharmaceuticals Inc. | 1 | $137 |
| AbbVie | 1 | $98 |
| GSK | 1 | $98 |
| EMD Serono, Inc. | 1 | $96 |
| E.r. Squibb & Sons, L.L.C. | 1 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $53 |
| Epizyme, Inc. | 2 | $49 |
| Bristol Myers Squibb | 2 | $37 |
| Pfizer | 1 | $29 |
| Genentech USA, Inc. | 1 | $28 |
| Novartis | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $17 |
| Novocure Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,976 in reported general payments places this provider in the 90th percentile of 181 primary care providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 42 | $594,331 |
| XtandiEnzalutamide | 33 | $438,001 |
| PomalystPomalidomide | 17 | $335,511 |
| Lenalidomide | 17 | $250,842 |
| TagrissoOsimertinib Mesylate | 15 | $246,937 |
| Abiraterone Acetate | 32 | $53,256 |
| EliquisApixaban | 11 | $8,934 |
| Anastrozole | 28 | $1,475 |
| Acyclovir | 15 | $312 |
| Gabapentin | 29 | $263 |
| Dexamethasone | 21 | $228 |
| Prednisone | 39 | $176 |
| Oxycodone Hcl | 26 | $157 |
| Prochlorperazine Maleate | 13 | $120 |
| LoperamideLoperamide Hcl | 15 | $115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $194 | $438,00133 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $95 | $335,51117 claims |
| AstraZenecaTagrisso | $280 | $246,93715 claims |
| PfizerEliquis | $29 | $8,93411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 181 primary care providers in Massachusetts.
Other primary care in Chelmsford
- Christine HatchNewburyport$11K
- Kate McCabeWinchester$11K
- Alyssa FelverLee$6K
- Katherine WatermanSpringfield$6K
- Joshua AbrahamsFoxborough$6K
- Glynelle WhiteFall River$6K
- Suhaiti VillaLawrence$5K
- Dmitry PrizandBoston$5K
- Ashley KoHaverhill$4K
- Melissa BorgesDartmouth$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.